Cibus (NASDAQ:CBUS) Issues Earnings Results, Misses Expectations By $0.09 EPS

Cibus (NASDAQ:CBUS) posted its quarterly earnings results on Thursday. The company reported ($0.29) EPS for the quarter, missing analysts’ consensus estimates of ($0.20) by ($0.09), FiscalAI reports. The firm had revenue of $0.80 million for the quarter, compared to the consensus estimate of $1.30 million. Cibus had a negative net margin of 2,258.89% and a negative return on equity of 287.03%.

Here are the key takeaways from Cibus’ conference call:

• Bio-fragrance opportunity expanded under a direct-sales model: Cibus estimates up to $100 million in peak annual revenue across eight ingredients, with projected gross margins of roughly 50%–70% and no expected manufacturing CapEx. Its first two ingredients are approved for the partner’s products and scale-up has begun, but revenue still depends on formulation success and purchase orders.
• Rice traits advanced toward customer testing and commercialization: Initial Latin American trials showed positive performance, and Interoc has planted Cibus-edited varieties in Ecuador, with results expected in the first quarter of 2027. Cibus targets a Latin American launch as early as 2028, though timing depends on trial results and commercialization planning.
• Near-term financing remains a significant risk: Cibus had $10.7 million in cash at quarter-end and expects it to fund planned expenses only into early Q1 2027; management said additional capital will be needed in the near term. The company reported a $21.9 million quarterly net loss.
• Spending discipline improved, while partner-funded programs progressed: Nine-month operating cash use fell about 19% year over year, and quarterly operating expenses declined roughly $2.7 million. Work began on partner-funded Indian mustard traits, while the U.K. light leaf spot program remained on schedule and pod-shatter material received approval for trial planting in England.

Cibus Price Performance

CBUS traded down $0.06 on Friday, hitting $1.03. The company had a trading volume of 54,555 shares, compared to its average volume of 352,237. Cibus has a 52-week low of $1.02 and a 52-week high of $4.19. The stock has a fifty day simple moving average of $1.44 and a 200-day simple moving average of $1.82. The firm has a market capitalization of $78.57 million, a P/E ratio of -0.61 and a beta of 1.65.

Analyst Upgrades and Downgrades

A number of equities research analysts have issued reports on CBUS shares. Wall Street Zen lowered shares of Cibus from a “hold” rating to a “sell” rating in a report on Saturday, October 17th. Weiss Ratings reaffirmed a “sell (e+)” rating on shares of Cibus in a research note on Friday, September 25th. One investment analyst has rated the stock with a Buy rating, one has issued a Hold rating and one has given a Sell rating to the stock. According to data from MarketBeat.com, the stock presently has a consensus rating of “Hold” and a consensus target price of $9.00.

Cibus Company Profile

Cibus is an agricultural technology company that develops plant traits using gene-editing technologies. Its proprietary Rapid Trait Development System (RTDS) is designed to make precise changes to a plant’s own genes, with the goal of developing useful crop characteristics without adding foreign DNA. The company’s research and development focuses on traits for crops including canola, rice and wheat, such as herbicide tolerance and resistance to crop diseases. Cibus aims to bring these traits to market through seed and technology licensing arrangements with partners in the agricultural industry.